A trial fibrillation (AF) is of public health importance and profoundly increases morbidity, mortality, and healthrelated expenditures. Morbidities include the increased risks of cardiovascular outcomes such as heart failure and stroke and the deleterious effects on quality of life (QOL), functional status, and cognition. The clinical epidemiology of AF, its risk factors, and its outcomes have been investigated extensively. Genetic advances over the last decade have facilitated the identification of mutations and common polymorphisms associated with AF. Metabolomics, proteomics, and other "omics" technologies have only recently been applied to the study of AF, and have not yet been systematically investigated. Systems biology approaches, although still in their infancy, offer the promise of providing novel insights into pathways influencing AF risk. In the present review, we address the current state of the epidemiology and genomics of AF. We seek to emphasize how epidemiology and omic advances will contribute to a systems biology approach that will help to unravel the pathogenesis, risk stratification, and novel targets for AF therapies. Our purpose is to articulate questions and challenges that hinge on integrating novel scientific advances in the epidemiology and genomics of AF. As a reference, we have provided a glossary in the online-only Data Supplement.
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Epidemiology AF: Increasing Burden and Burgeoning Costs
In the United States and Western Europe, the aging of the population and the accompanying rise in the prevalence of AF have magnified its toll on morbidity and healthcare costs. The estimated US prevalence of 2.7 to 6.1 million is expected to increase to 5.6 to 12.1 million by the middle of this century ( Figure 1 ). 1, 2 Cumulative lifetime risk estimates demonstrate that AF is largely a disease of aging. In US and European community-based cohort studies, the lifetime risk of AF is 22% to 26% in men and 22% to 23% in women by 80 years of age ( Figure 2 ). 3, 4 AF risk doubles with each progressive decade of age; Ͻ1% in individuals 50 to 59 years of age are affected, whereas Ϸ10% of those 80 to 84 years and 11% to 18% of those Ն85 years of age have AF. 1, 2, 5 The increasing prevalence of AF has resulted in greater healthcare use and costs. From 1985 through 1999, hospitalizations for AF increased nearly 3-fold. 6 A recent analysis of medical costs associated with AF used commercial and Medical databases representing Ϸ38 million individuals in the United States. The study used propensity-matching techniques to determine that individuals with AF had 73% higher medical costs compared with matched control subjects. The incremental cost was $8075 per individual with AF in the United States, resulting in a total national incremental cost ranging from $6.0 to $26.0 billion in 2008 values. 7 Data from Western Europe similarly have demonstrated escalating resources consumed by AF hospitalizations. 8 -12 The increased healthcare costs reflect sequelae of AF, including heart failure, dementia, stroke, and mortality. Clinical trial registries have established a direct increase in the prevalence of AF with each successive New York Heart Association class. 13 In population-based studies, the incidence of heart failure among individuals with AF ranged from 33 14 to 44 15 per 1000 person-years. Concomitant heart failure with AF is associated with a particularly adverse prognosis. In Framingham Heart Study participants with AF, the onset of heart failure was associated with a tripling in mortality compared with those with AF alone. 14 Similarly, in an adjusted meta-analysis of observational heart failure studies, AF was associated with increased mortality (odds ratio, 1.14; 95% confidence interval [CI], 1.03-1.26; PϽ0.05). 16 In longitudinal community-based analyses, AF is associated with an increased risk of silent and clinically evident stroke. 17 With nonrheumatic AF, the risk of stroke is increased Ϸ5-fold. Compared with strokes without AF, strokes occurring in the setting of AF have greater severity, tend to be more disabling, and have an increased risk of mortality compared with strokes of other origins (30-day mortality odds ratio, 1.84; 95% CI, 1.04 -3.27). 18 In addition, AF is associated with a 2-fold increased risk of silent cerebral infarction (odds ratio, 2.16; 95% CI, 1.07-4.40). 19 Medicare registries and clinical trials have demonstrated the protective effect of warfarin on reducing stroke events. 20, 21 Furthermore, subtherapeutic anticoagulation results in 5 times the odds of an ischemic stroke. 22 Multiple alternatives to warfarin, ie, factor IIa and Xa antagonists, have successfully been developed for AF stroke prevention. 23 Ongoing challenges include long-term studies assessing adherence, cost-effectiveness, QOL, and access to such agents.
Individuals with AF have a 1.7-fold odds of impaired cognitive function (95% CI, 1.2-2.5) and a 2-fold increased odds for dementia even after adjustment for anticoagulation status (odds ratio, 2.3; 95% CI, 1.4 -3.7). 24 Similarly, there is evidence that decreased time in the therapeutic range while on anticoagulation therapy is associated with impaired cognition. 25 In Olmsted County, the cumulative rate of dementia in individuals with AF exceeded 10% at the 5-year follow-up and contributed to an almost 3-fold increased mortality risk (hazard ratio, 2.98; 95% CI, 2.5-3.3). 26 Increased symptoms, diminished functional performance, and decreased QOL are receiving more attention as metrics for gauging AF treatments. Symptoms have been incorporated into AF guidelines as therapeutic targets, yet a lack of agreement on standardized symptom ascertainment remains. The significant adverse association of AF with impairments in physical, mental, cognitive, and social QOL domains has been documented. 27 However, the relation between QOL metrics in individuals with AF and clinical end points such as heart failure, stroke, and mortality has had limited investigation. 28 An analysis in the Canadian Trial of Atrial Fibrillation showed improvement in QOL with AF treatment. The study was limited by 12 months of follow-up, was small in size, and was made up primarily of individuals with preserved cardiac function. 29 In longer follow-up, the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study identified no difference in QOL outcomes in the rate or rhythm control strategy arms. 30
AF Epidemiology: Future Directions
There remains a paucity of epidemiological data on AF from many parts of the world, including Eastern Europe, Africa, and South America. Recent epidemiological investigations in China and Japan reported that the AF prevalence was less than that in the United States and in European countries. 31, 32 Furthermore, the effects of industrialization and urbanization on AF incidence have not been ascertained. Marshaling resources in areas with social and economic challenges will remain an obstacle in the estimation of the global burden of AF.
AF ascertainment, monitoring, and classification in ethnic and racial minorities also have been limited. Much of the AF epidemiology described here was developed in cohorts of European descent. Classification schemes and treatment guidelines have been developed from studies limited by racial and ethnic homogeneity. The longitudinal risk factors, outcomes, and quantification of the burden of AF in ethnic/racial minorities need further elucidation.
Fundamental questions remain concerning AF subsets and the life course of AF, including the long-term assessment of the occurrence, recurrence, and progression of AF from onset until death. Guidelines and classification schemes describe AF as first detected 33 (first diagnosed 34 ), paroxysmal, persis- tent, or permanent. 33 However, the classifications have clinical and epidemiological limitations in that an individual's classification may be evident only retrospectively, and the durations embedded in the classification system are somewhat arbitrary. Likewise, it is uncertain how AF in the setting of acute illness, decompensation, or trauma relates to risk of subsequent AF. In addition, lone AF is a well-recognized clinical entity, and its environmental milieu and triggers merit continued investigation.
QOL and symptoms metrics have been introduced only recently, 35 but have not become a standardized component for clinical trial, epidemiological study, or clinical practice. How QOL measures are affected by the comorbidity and burden of AF requires continued investigation. The intersections of QOL, aging, and AF have similarly not been well explored; nor has the relation of AF to diminished functional status and frailty.
Clinical Risk Factors of AF
Standard AF risk factors may be summarized succinctly as older age, male sex, smoking, obesity, hypertension, diabetes mellitus, myocardial infarction, heart failure, valvular heart disease, and cardiac surgery. 36 -39 Figure 3 depicts the population-attributable risk for AF risk factors in a longitudinal community-based study. 36 The biracial Atherosclerosis Risk in Communities (ARIC) recently reported that 56.5% of the population-attributable risk was explained by having at least 1 borderline or elevated risk factor, with high blood pressure being the most important risk factor. 40 Although a prominent component of the population-attributable AF risk remains unknown, the ARIC data suggest important opportunities for AF prevention through risk factor modification.
The increasing prevalence of many AF risk factors, including the aging of the population, obesity, and diabetes mellitus, coincides with the rising prevalence of AF. Age is a foremost risk factor for AF 41 ; from 2010 to 2050, the US population Ն65 years of age is expected to increase from 13.0% to 20.2%, and the population Ն85 years from 1.9% to 4.3%. 42 Similarly, the prevalence of obesity, now up to one third of the US population, 43 may contribute to an increase in the prevalence of AF. Obesity has been associated with an increase in AF risk from 1.5-to 2.3-fold in community-based cohorts, with follow-up ranging from 5 to 14 years. 37, 38, 44 Obesity (hazard ratio, 1.54; 95% CI, 1.2-2.0) and severe obesity (hazard ratio, 1.87; 95% CI, 1.4 -2.5) are associated with progression from paroxysmal to permanent AF over a median 5-year follow-up. 45 Obstructive sleep apnea, rising in prevalence with obesity, also is associated with increased AF risk (odds ratio, 2.19; 95% CI, 1.40 -3.42). 46 Miscellaneous risk factors for AF that have been reported include hyperthyroidism, 47, 48 alcohol use, 49 -51 and exercise. [52] [53] [54] [55] [56] Of interest, for both alcohol and physical activity, a threshold effect has been reported wherein increased risk of AF was observed only in individuals with heavy alcohol consumption 51 or frequent vigorous exercise. 56
Indexes of AF Risk: Biomarkers and Intermediate Phenotypes
Multiple biomarkers have been assessed for their association with AF. N-terminal pro-B-type natriuretic peptide has been associated with a multivariable-adjusted, 4-fold increased risk of AF in 10-year median follow-up (hazard ratio, 4.0; 95% CI, 3.2-5.0) in a comparison of the highest and lowest quartiles in a longitudinal community-based study. 57 Inclusion of N-terminal pro-B-type natriuretic peptide likewise significantly strengthened an AF risk score derived in a community-based cohort. 58 Interleukin-6 has been elevated in participants with AF in diverse cohorts, including individuals with chronic AF and coronary artery disease. 59, 60 Other biomarkers associated with incident or recurrent AF include osteoprotegerin, 61 troponin, 62,63 endothelin, 63 and plasminogen activator inhibitor-1. 64 P-wave indices, ECG markers of intra-atrial and interatrial conduction, have been proposed as noninvasive markers of electric remodeling. The vectorcardiographic measurements of P-wave duration, area, terminal force, and dispersion have been used in AF risk prediction. 65, 66 Associated with age, sex, diabetes mellitus, body mass index, and waist circumference, 67 P-wave indices serve as intermediate phenotypes of AF risk and reflect the delayed atrial conduction described in the setting of atrial inflammation, structural remodeling, and progressive atrial fibrosis. 68 -70 Left ventricular hypertrophy also has been reported to predict new-onset AF in prospective analysis. 71 Echocardiographic predictors of AF have effect size estimates similar to those of ECG predictors and include increasing left atrial diameter and left ventricular wall thickness and decreasing left ventricular systolic function. 72 Risk score development has received increasing attention in AF epidemiology. Risk scores serve multiple purposes, including providing benchmarks against which to test novel risk markers, assisting as tools for risk estimation and communication with patients, and identifying low-or highrisk individuals in decisions regarding clinical management or clinical trial enrollment. The AF risk score of the Framingham Heart Study identified significant predictors for AF risk, including age, male sex, treatment for hypertension, significant cardiac murmur, history of heart failure, and increasing body mass index, blood pressure, and PR interval. 73 The Figure 3 . The population-attributable risk of atrial fibrillation in men and women determined from a community-based longitudinal study. 36 For both men and women, a substantial portion of atrial fibrillation risk remains unexplained. MI indicates myocardial infarction; HTN, hypertension; HF, heart failure; VHD, valvular heart disease; DM, diabetes mellitus; and LVH, ECG left ventricular hypertrophy.
Framingham model's c statistic was 0.78 (95% CI, 0.76 -0.80). 73 In subsequent models developed in the ARIC study, 71 the Age, Gene/Environment Susceptibility-Reykjavik Study, and the Cardiovascular Heart Study, 74 similar predictive abilities were achieved. The ARIC Study AF risk score validated the Framingham model, achieving a c statistic of 0.68 in the ARIC cohort. The ARIC study also developed a novel study-specific risk score that included adjustment for race and achieved a c statistic of 0.78. 71 C-reactive protein and natriuretic peptides significantly enhance reclassification for risk of AF. 58
AF Risk Factors: Future Directions
Racial differences in AF remain poorly understood. Overall, blacks have a higher prevalence of multiple AF risk factors (obesity, diabetes mellitus, hypertension, and heart failure), 75 yet lower incidence of AF. 1, 76 In the ARIC study, the cumulative risk of AF at 80 years of age reached 21% in white men and 17% in white women, but was only 11% in black men and women. 77 The contrasting burden of risk factors with decreased AF incidence has been called a "racial paradox." 78 There is limited understanding of the biological and pathophysiological differences modulating the racial differences in AF. An analysis of the Heart and Soul Study identified racial differences in left atrial dimensions. 79 Racial variation in P-wave indices has been identified in both the ARIC study and National Health and Nutrition Examination Survey (NHANES III). 65, 80 Some of the racial paradox of AF may be mediated by genetics. In a biracial meta-analysis of the Cardiovascular Health Study and ARIC study using ancestry informative genetic markers, European ancestry was identified as a risk factor for AF (estimated hazard ratio per 10% increase in European ancestry, 1.17; 95% CI 1.07-1.29). 81 Biomarkers represent important opportunities for their role in AF risk assessment, and criteria to evaluate new markers have been articulated. 82 Numerous candidate biomarkers representing inflammatory, hemostatic, oxidative stress, matrix remodeling, and neurohormonal pathways may be tested for their associations with AF risk. We advocate a rigorous methodology for examining the value of putative novel biomarkers (or subclinical testing measure) in risk prediction. Biomarker assessment requires metrics of discrimination, calibration, and risk reclassification. Providing independent replication of the relation between AF and 1 biomarker or clusters of biomarkers will further strengthen the credibility and utility of biomarkers in assessing AF risk. Finally, putative biomarkers should add incremental information over and above established AF predictors to demonstrate their value.
Dietary risk factors in AF epidemiology have had limited exploration, likely from challenges from longitudinal tracking of accurate exposures, as recently reviewed. 83 There have been contrasting findings on the protective effect of consumption of specific kinds of fish on AF prevention. 84, 85 Long-term, highly accurate monitoring of nutritional intake or development of nutritional biomarkers is essential for clarifying dietary contributions to AF risk. The clinical and genetic interactions augmenting such risk also have not been explored. Finally, environmental exposures such as carbon monoxide and air pollution and their associations with AF risk have not been examined in community-or populationbased studies.
Genetics of AF

Familial AF
The familial nature of AF was reported as early as 1942. 86 In the ensuing 50 years, there were infrequent reports of similar families with an apparent mendelian inheritance of AF. In 1997, Brugada and colleagues 87 described the first genetic locus for AF; however, the causative gene at the locus remains elusive. In 2003, Chen and colleagues 88 described the first mutation in a Chinese family with early-onset AF. The causative mutation resulted in a gain of function in KCNQ1 (the ␣ subunit of I Ks ). In subsequent years, multiple mutations have been identified in potassium 88 -93 and sodium 94 -96 channels, gap junction proteins, 97 and signaling molecules. 98 However, screening each of the identified genes has revealed few additional mutations in families with AF. 99, 100 Thus, unlike other familial monogenic cardiac disorders, such as hypertrophic cardiomyopathy and long-QT syndrome, wherein a finite set of genes are responsible for the vast majority of the cases, AF is more genetically heterogeneous. 99, 100 Although familial AF has long been recognized, it has only recently been appreciated that AF occurring in the general population is heritable. In the Framingham Heart Study, a parental history of AF was shown to nearly double AF risk in offspring. 101 More recently, familial AF and premature familial AF improved discrimination and categoryless reclassification of AF risk. 102 Similarly, investigators from Iceland found that the risk of AF approached nearly 2-fold in first-degree relatives of those with AF (risk ratio, 1.77; 95% CI, 1.67-1.88) and increased even further with an earlier age of AF onset. 103 Finally, in a study of Danish twins, monozygotic twins were significantly more likely to be concordant for AF than dizygotic twins. 104
Genome-Wide Association Studies Have Identified 3 Loci for AF
The application of genome-wide association studies (GWAS) to AF has the potential to transform our understanding of molecular mechanisms underlying the arrhythmia. In large cohorts, GWAS use single-nucleotide polymorphisms as markers of genetic variation between affected and unaffected individuals. High-density genotyping arrays now combine the power of association studies with systematic genome-wide research. In contrast with candidate gene studies, GWAS arrays are unconstrained by preexisting knowledge of which genes contribute to disease. To date, AF GWAS have been successful in identifying 3 novel genetic loci. [105] [106] [107] [108] [109] The first locus, on chromosome 4q25, is upstream of the gene PITX2. 107, 109 PITX2 encodes for the paired-like homeodomain transcription factor 2 that is a plausible candidate gene for AF, albeit unrecognized as such before the first AF GWAS. Mommersteeg et al 110, 111 demonstrated that PITX2cdeficient mice fail to form embryonic pulmonary myocardial cells, and as a result lack pulmonary myocardial sleeves. The PITX2c isoform suppresses the default formation of a sinus node in the left atrium. In the last year, 2 additional studies have advanced our understanding of the role of PITX2c in AF. Wang et al 112 have demonstrated that PITX2c is expressed in postnatal mouse left atria, pulmonary veins, and right ventricles and that PITX2c Ϫ/Ϫ predisposes mice to atrial arrhythmias. Furthermore, microarray analysis revealed that in PITX2c Ϫ/Ϫ mice, gene expression in sinus node tissue was upregulated. Upregulated genes included SHOX2 and TBX3, in addition to multiple channel genes (including KCNQ1). 112 Similarly, in human atrial tissue, Kirchhof et al 113 found that PITX2 expression levels were Ϸ2 orders of magnitude higher in the left atrium compared with the right atrium or the ventricles. PITX2c heterozygote mice had shorter atrial action potential durations compared with the wild type and were susceptible to AF induced by pacing, whereas no differences in cardiac morphology, including interstitial fibrosis and function, were observed. 113 However, although PITX2 is an attractive candidate gene for AF at this locus, the precise mechanism through which PITX2 or other genes at this locus result in AF remains unknown.
The second genetic locus for AF is located at the transcription factor ZFHX3 on chromosome 16q22. ZFHX3 (also known as ATBF1) encodes the transcription factor zinc finger homeobox protein 3 and is expressed primarily in the brain but also has been isolated in myocardium. 114 The mechanism through which genetic variation at this locus relates to AF is unclear.
The third locus for AF is intronic to the calcium-activated potassium channel KCNN3 on chromosome 1q21. 106 The KCNN3 (or SK3) channel is part of a family of Ca 2ϩ -activated potassium channels gated by changes in intracellular Ca 2ϩ concentration. 115 KCNN1 (SK1) and KCNN2 (SK2) channels have predominantly atrial expression. In contrast, KCNN3 channels are equally distributed in atria and ventricles. In human and mouse cardiac repolarization models, KCNN3 channels have a prominent role during the late phase of the cardiac action potential. 116 -118 Li et al observed action potential duration prolongation and an increased number of early afterdepolarizations in the atrial myocytes of KCNN2 Ϫ/Ϫ knockout mice. 119 Atrial arrhythmias, mainly pacing-induced AF, were more frequent in both heterozygous and homozygous KCNN2 mice. 119 Interestingly, familial occurrence of AF remains a risk factor for AF even after adjustment for the 3 genetic variants identified by GWAS. 102 Figure 4 displays the 3 loci on a Manhattan plot, providing a means of illustrating their chromosomal position and statistical significance in meta-analyses. In addition, multiple genetic loci related to AF or established risk factors for AF have been identified throughout the genome. The multiple loci are illustrated in Figure 5 , which is intended to indicate the number of loci, their proximity, and their relations. 120 As discussed below, such a map may inform the development of a genetic systems-based approach to AF.
GWAS of AF: Future Directions
Whereas recent advances with GWAS have identified potential new pathways for AF, the reported genomic loci contribute minimally to the risk of AF in the population. So far, studies of familial AF have discovered rare, highly penetrant genetic variants of AF. In contrast, candidate gene studies and GWAS have revealed more common genetic variants with smaller effect sizes in AF cohorts and the general population ( Figure 6 ). However, a large proportion of the heritability of AF cannot be explained by genetic variants reported to date. It has been postulated that the missing heritability of most common diseases, such as AF, may be explained partially by low-frequency variants with intermediate effect sizes ( Figure  6 ). 121, 122 Advances in sequencing technologies may make it possible to detect these low-frequency genetic variants rapidly and reliably. Whether exome sequencing and potentially whole-genome sequencing studies will be able to uncover a substantial portion of the missing heritability of AF remains to be determined.
Finally, the contributions of structural variation 123 to AF risk require investigation. Structural variation refers to the array of genomic microscopic and submicroscopic diversity within the human genome. Specific examples include copynumber variants, deletions, insertions, and other components introducing genomic heterogeneity. 124 Unidentified structural variants may contribute to the heritability of AF, augment AF risk, or indirectly mediate AF risk through other clinical pathways. Furthermore, exploration of structural variants may yield insights into gene-gene and gene-environment pathways for AF risk, which have had only limited investigation. Pϭ6.3ϫ10 Ϫ18 ) in Icelandic individuals diagnosed with AF at Յ60 years of age. 108 The second locus, associated with ZFHX3, identified 3 SNPs with relative risk ranging from 1.26 to 1.65. 105 The third and most recently published SNP identified on the 4q25 locus had an OR of 2.03 (95% CI, 1.79 to 2.30; Pϭ2.5ϫ10 Ϫ28 ). 106 Modified from Ellinor et al with permission of the publisher. 106 Copyright © 2010, Nature Publishing Group.
"Omics" in AF: Current Status and Future Directions
To fill the gap between genetic variants and the development of AF, new advances are being made in the field of epigenomics, transcriptomics, proteomics, and metabolomics. Epigenetic phenomena such as DNA methylation or histone modifications may alter gene expression, thereby influencing the potential impact of changes in the DNA sequence. 125 Research in the expansive fields of "omics" is emerging rapidly. Although such endeavors will elucidate novel pathways in the initiation and maintenance of AF, "omics" research is still in its infancy. Two recent advances demonstrate the utility of "omics" data in AF investigation but also illustrate the challenges in interpretation. First, individuals with permanent AF were demonstrated to have upregulation of transcripts involved in metabolic activities, specifically multiple glycolytic enzymes, thereby suggesting upregulation of glucose metabolism during AF. 126 Second, transcriptomic and proteomic analysis in individuals with persistent AF identified a rise in ketone bodies, suggesting that ketone bodies may contribute to negative feedback on glucose metabolism. 127 Figure 5 . Circos 120 plot representing the genetic variants found by genome-wide association study for atrial fibrillation (AF) and AF risk factors. The outer ring represents the chromosomes; the inner rings detail the location of different single-nucleotide polymorphisms related to AF and AF risk factors. The colors represent each phenotype or AF risk factor. BMI indicates body mass index; CHD, coronary heart disease; CRP, C-reactive protein; CSF, cardiac structure and function; DBP, diastolic blood pressure; DM, diabetes mellitus; ECG, electrocardiographic traits; echo, echocardiographic traits; HF, heart failure; HTN, hypertension; MI, myocardial infarction; PR, PR interval; and SBP, systolic blood pressure. See the onlineonly Data Supplement for methods. Figure 6 . Summary of the identified genetic associations of atrial fibrillation (AF) and future areas of genetic study. Investigators have identified mendelian families with AF genes having large effect size but rare frequency. Both candidate gene studies and genome-wide association studies (GWAS) have identified variants and loci with low to modest effect sizes. Among the 2 study types, candidate gene studies have tended to report larger effect sizes. Such an overestimation of effect size has been described in a phrase borrowed from economics as the "winner's curse." In contrast, GWAS have identified 3 distinct loci with low to modest effect sizes. Sequencing efforts may fill a substantive genomic gap by identifying unrecognized low-frequency variants with moderate effect sizes. Because a prominent component of the population-attributable risk (see Figure 3 ) remains unknown, further genetic study may contribute additional insights into the origin of AF. Modified from Manolio et al with permission of the publisher. 121 Copyright © 2011, Nature Publishing Group.
Published transcriptomic and proteomic investigations need to be interpreted with some caution. The study samples were typically small, and the findings have not yet been replicated. Analysis of atrial tissue is complicated by anatomic and physiological variability. 126 AF is a highly heterogeneous disease, with multiple contributing mechanisms, predisposing risk factors, and conditions. Patient dissimilarities by age, sex, race, risk factors, AF patterns, medication use, and underlying comorbid conditions may contribute to variability in gene expression.
Regulatory loops involving microRNAs are intermediate regulators and modifiers of genes. Although microRNAs may serve as broad regulatory mechanisms of an entire pathway, most of their targets and precise elements of their regulation have not been clarified. MicroRNAs have been linked to fibrotic and apoptotic pathways that may contribute to AF susceptibility via electric or structural remodeling. 128 Several microRNAs have been targeted for their involvement in AF on the basis of their regulation or association with genes encoding cardiac ion channels or Ca 2ϩ -handling proteins. In both animal models and humans with AF, Ͼ3-fold upregulation of microRNAs specific to calcium channel subunits has been identified from atrial tissue. 129 In a cardiac surgery series (nϭ62, half of whom had AF), left atrial samples from individuals with AF demonstrated significantly reduced levels of a microRNA associated with potassium channel regulation. 130 Important challenges remain for the study of microRNAs in AF. There is redundancy in microRNAs targeting specific genes; likewise, single microRNAs may have multiple genetic targets. How the multiplicity of effects contributes to AF and intermediate pathways for AF such as cardiac hypertrophy and failure renders the interpretation of microRNAs even more challenging. 131 In addition, variable microRNA expression in specific patterns of AF (eg, newly diagnosed, paroxysmal, persistent, or permanent AF) or in the setting of clinical or genetic risk factors requires study. Prospective investigations such as those conducted by Lu et al 129 may provide insights into microRNA expression across the spectrum of AF.
Systems Biology: Application to AF
AF epidemiology and genetic investigations stand at an intellectual and scientific crossroad. Similar to many medical fields, 132 much of the prior work in AF has applied a reductionist approach, using an exposure-disease paradigm for understanding AF and its risk factors. Most prior genetic epidemiology similarly has used a 2-dimensional framework for examining genome-wide associations.
Accumulating evidence indicates that complex diseases are usually influenced by the interactions of multiple genes, which are incompletely captured by single-gene-based approaches. [133] [134] [135] Furthermore, biological systems comprise circuitries of interacting components such as proteins, nucleic acids, and other small molecules that operate in concert to create complicated molecular networks. 136 -139 Added to such myriad factors are gene-gene and gene-environment interactions, followed in turn by longitudinal epidemiological risk factor modification.
The paradigm of systems biology provides novel and important opportunities for combining the classic epidemiology of exposure-disease association, genetic associations, "omics," and molecular investigations. A systems biology approach 132 departs from the linear investigation of exposuredisease or gene-phenotype and seeks to investigate a network of interconnected hierarchies from the cellular to the population level. Informed by the preceding stage of investigation, systems biology networks will facilitate examination of the relations between genome, epigenome, transcriptome, proteome, metabolome, and clinical (environmental) risk factors and their connection to the phenome of interest. Systems biology models the complex interactions among the multiple epidemiological, genomic, and omic arenas, combining and distilling hierarchies to generate nonlinear understanding of disease pathogenesis. 140, 141 Figure 7 illustrates selected components that may be integrated in a systems biology approach to AF. Ultimately, we anticipate that systems biology will provide a mechanistic basis for discerning phenotypic differ-ences among individuals with AF through the development of the interactome of network-based approaches integrating "omic" and environmental factors. 141 By identifying and characterizing the components of a biological system, systems biology can examine the interaction and hierarchical association between the distinct components. 142, 143 Systems biology has not had application to AF research, and its potential has not yet been realized. As an iterative process, the systems biology approach will require repeated experimentation and refinement. No large studies of AF have conducted the comprehensive cell-to-cohort integration of systems networks that we envision. Future systems biology efforts will be most effective if they incorporate work across disciplines, including cellular and clinical electrophysiology, in vitro and animal science, genomics, epidemiology, bioinformatics, and statistics. Finally, we are a full generation from a systems biology that integrates longitudinal geneenvironment and risk exposures in developing networks for modeling AF risk. More realistically, we anticipate that in the future systems biology will inform basic and epidemiological investigations, reminding us that the complex expression of AF is not limited to isolated exposures or genetic loci.
Conclusions
AF has profound clinical and public health burdens, which have grown over the last several decades. Epidemiological approaches have determined the major clinical risk factors, but there are large areas of uncertainty. Robust biomarker assessment, racial and global variation, and dietary and environmental exposures are some persistent areas that require epidemiological investigation and clarification. We hope that a better understanding of AF risk factors and risk stratification will accelerate efforts at prevention.
Advances by GWAS have identified new genomic loci associated with AF risk but explain very little of the population-attributable risk for AF. "Omics" studies, still in early development and confined to small experimental studies and clinical samples, provide new avenues for identifying cellular and developmental pathways for AF. We advocate the importance of developing a systems biology approach that will integrate experimental and clinical data across multiple disciplines and "omics" studies. The Table summarizes gaps and research opportunities discussed in this review that are critical to address to accelerate discovery. We envision that systems biology, informed by population-based epidemiology, will identify phenotypic traits, integrate genetic loci, and use "omics" platforms to provide new insights into the pathogenesis, prevention, risk prediction, and therapeutic strategies for AF. 
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